Pacitti Group Inc. Purchases Shares of 3,906 Danaher Co. (NYSE:DHR)

Pacitti Group Inc. bought a new position in Danaher Co. (NYSE:DHR) during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 3,906 shares of the conglomerate’s stock, valued at approximately $564,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. EP Wealth Advisors LLC grew its position in Danaher by 33.1% in the third quarter. EP Wealth Advisors LLC now owns 2,706 shares of the conglomerate’s stock worth $391,000 after acquiring an additional 673 shares in the last quarter. Equitable Trust Co. grew its position in Danaher by 4.0% in the third quarter. Equitable Trust Co. now owns 32,316 shares of the conglomerate’s stock worth $4,667,000 after acquiring an additional 1,249 shares in the last quarter. Global Retirement Partners LLC grew its position in Danaher by 20.4% in the third quarter. Global Retirement Partners LLC now owns 4,381 shares of the conglomerate’s stock worth $633,000 after acquiring an additional 742 shares in the last quarter. Carnegie Capital Asset Management LLC grew its position in Danaher by 6.0% in the third quarter. Carnegie Capital Asset Management LLC now owns 2,472 shares of the conglomerate’s stock worth $357,000 after acquiring an additional 140 shares in the last quarter. Finally, J.P. Marvel Investment Advisors LLC purchased a new position in Danaher in the third quarter worth $3,504,000. Hedge funds and other institutional investors own 78.10% of the company’s stock.

Several research analysts recently issued reports on the stock. Needham & Company LLC cut their target price on shares of Danaher from $155.00 to $152.00 and set a “buy” rating for the company in a research report on Monday, October 28th. Wolfe Research set a $154.00 target price on shares of Danaher and gave the stock a “buy” rating in a research report on Friday, October 25th. Stifel Nicolaus reiterated a “hold” rating and issued a $150.00 target price on shares of Danaher in a research report on Thursday, November 14th. ValuEngine lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, UBS Group upped their price target on shares of Danaher from $158.00 to $165.00 and gave the company a “buy” rating in a research report on Monday. Five investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Danaher currently has an average rating of “Buy” and a consensus price target of $147.53.

DHR stock traded up $0.62 during trading on Wednesday, reaching $147.31. The company had a trading volume of 13,548,045 shares, compared to its average volume of 2,781,017. Danaher Co. has a 52 week low of $94.59 and a 52 week high of $149.61. The company has a market cap of $104.85 billion, a P/E ratio of 32.59, a PEG ratio of 2.45 and a beta of 0.92. The business has a 50 day moving average of $139.75 and a 200 day moving average of $139.74. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.43 and a quick ratio of 3.09.

Danaher (NYSE:DHR) last released its quarterly earnings results on Thursday, October 24th. The conglomerate reported $1.16 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.15 by $0.01. Danaher had a net margin of 12.13% and a return on equity of 11.42%. The company had revenue of $5.04 billion during the quarter, compared to the consensus estimate of $5.02 billion. During the same period in the prior year, the firm earned $1.10 earnings per share. Danaher’s revenue was up 3.8% on a year-over-year basis. Research analysts expect that Danaher Co. will post 4.76 earnings per share for the current year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

Featured Story: Net Margin – Understanding the Different Kinds of Profit

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.